Biodesix/Aveo: A Harbinger Of Deals To Come
Aveo Pharmaceuticals and Biodesix have entered into a worldwide agreement to develop and commercialize Aveo’s ficlatuzumab, an antibody that inhibits hepatocyte growth factor, using Biodesix’s serum-based companion diagnostic VeriStrat, which guides treatment decisions for patients with advanced non-small cell lung cancer.
You may also be interested in...
With current technology and resources, a well-funded in vitro diagnostics company can create and pursue a strategy of information gathering and informatics application to create medical knowledge, enabling it to assume the risk and manage certain segments of patients. But few if any pharma or diagnostics firms appear poised to take advantage.
Zydus Cadila expects domestic sales to improve and the US generics business to grow in “mid to high” single digits during FY21 after both saw a coronavirus-related hit in Q1. Meanwhile, approvals for a few biologics are expected, its COVID-19 vaccine candidate has just entered Phase II studies and remdesivir launch looms.
At-home nail and hair care and e-commerce were bright spots in a numbing second quarter for Revlon, which was hit hard by mass retail and salon channel closures at a time of ongoing transformation.